Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_1

33%

Ph not_applicable

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 1

Trials by Phase

Phase 11 (33.3%)

N/A2 (66.7%)

Trials by Status

terminated133%

completed267%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_1

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

NCT04730583

terminatednot_applicable

Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone

NCT03639857

completednot_applicable

Evaluation of the Safety and Precursors of Efficacy

NCT02098811

Clinical Trials (3)

Showing 3 of 3 trials

NCT04730583Phase 1

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

Completed

NCT03639857Not Applicable

Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone

Terminated

NCT02098811Not Applicable

Evaluation of the Safety and Precursors of Efficacy

Completed

All 3 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 3